cGMP production of MSCs

Derek J. Hei, David H. McKenna

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Over the past decade, mesenchymal stromal/stem cells (MSCs) have evolved into an important cell therapy demonstrating potential utility in a range of clinical applications, including bone and cartilage repair, cardiac repair, and immune disorders. MSCs can be isolated from a variety of tissue sources, including bone marrow, adipose tissue, dental pulp, and placenta. Groups have developed different manufacturing processes with a goal of improving the quality of clinical-grade cells and the overall efficiency of the manufacturing process. Variations in cell source and manufacturing process may have a significant impact on the efficacy of the final MSC product. Moreover, this variability in cell source and manufacturing processes has made it challenging to compare the resulting MSC products and associated results from clinical trials that have been conducted to date. The development of consistent, well-controlled manufacturing processes along with the implementation of thorough quality control testing, including rigorous potency assays, will insure high quality and may help to clarify the impact of cell source and manufacturing process on the resulting MSC product. In addition to providing an overview of the current good manufacturing practice (cGMP) methods for MSC production, this chapter summarizes key FDA regulatory requirements, including those related to cell source, raw materials, and quality control testing.

Original languageEnglish (US)
Title of host publicationMesenchymal Stromal Cells
Subtitle of host publicationBiology and Clinical Applications
PublisherSpringer New York
Pages317-341
Number of pages25
ISBN (Electronic)9781461457114
ISBN (Print)9781461457107
DOIs
StatePublished - Jan 1 2013

Fingerprint Dive into the research topics of 'cGMP production of MSCs'. Together they form a unique fingerprint.

Cite this